Tim Funnell
Director
Tim is a Founding Partner of Monograph Capital and leads the firm's London office for life sciences investments.
He represents a transatlantic portfolio including: RQ Biotechnology, Elevara, Maxion, Aviado, Ascend and Ouro Medicines (acquired by Gilead).
Prior to Monograph Capital, Tim was co-founder of MiroBio (also acquired by Gilead). Tim has been a biotech investor and company-builder at Syncona, Third Rock Ventures, and Oxford Sciences, gaining experience across therapeutic modalities and geographies.
He began his career at the Boston Consulting Group in London. Tim trained as a pharmacologist, with an undergraduate degree from the University of Cambridge and a DPhil from the University of Oxford.